Updated cholesterol guidelines introduce important changes in cardiovascular risk assessment and lipid management that directly impact pharmacist practice. This course reviews key updates from the new ACC/AHA dyslipidemia guideline, including risk assessment tools, LDL-C targets, and evolving roles for statin and nonstatin therapies. You will be better prepared to identify practice-relevant recommendations and support evidence-based lipid management in patient care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

Janelle Ruisinger, PharmD, FAPhA
Associate Dean for Academic Affairs and Clinical Professor
The University of Kansas School of Pharmacy

GET CE FOR LISTENING!
Stay Compliant. Grow Clinically. Practice with Confidence. 

Pharmacist CE Subscription: All your CE in one convenient subscription.
All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there’s even more!

The Pharmacist CE Subscription includes: 
-  Compliance and licensure CE 
-  GameChangers Clinical Updates 
-  Practical continuing education across patient care topics 

*The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. 

Purchase Now!

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription.

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here. 

CPE INFORMATION

Learning Objectives

Upon successful completion of this knowledge-based activity, participants should be able to:

1. Describe key pharmacist-relevant updates in the new ACC/AHA Guideline for the Management of Dyslipidemia.

2. Differentiate risk assessment and lipid-lowering treatment considerations that may influence pharmacist recommendations under the updated guideline.

Rachel Maynard and Janelle Ruisinger have no relevant financial relationships to disclose.

0.75 CEU/0.75 Hr
UAN: 0107-0000-26-156-H01-P
Initial release date: 5/4/2026
Expiration date: 5/4/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram